TCM
NVCR icon

Tekla Capital Management’s NovoCure NVCR Stock Holding History

Tekla Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-87,918
Closed -$15.2M – 212
2020
Q4 		$15.2M Sell
87,918
-28,927
-25% -$3.96M 0.53% 53
2020
Q3 		$13M Sell
116,845
-14,792
-11% -$1.18M 0.49% 53
2020
Q2 		$7.81M Buy
131,637
+24,199
+23% +$1.59M 0.3% 71
2020
Q1 		$7.24M Hold
107,438
– – 0.33% 61
2019
Q4 		$9.05M Buy
107,438
+6,506
+6% +$525K 0.34% 70
2019
Q3 		$7.55M Buy
100,932
+46,858
+87% +$3.75M 0.33% 60
2019
Q2 		$3.42M Sell
54,074
-11,890
-18% -$602K 0.14% 111
2019
Q1 		$3.18M Buy
65,964
+41,464
+169% +$2M 0.13% 117
2018
Q4 		$820K Buy
+24,500
New +$896K 0.04% 170

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tekla Capital Management's NVCR Position: Q1 2021 in Review

Tekla Capital Management sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 87,918 shares — an estimated $15.2M sold.

Tekla Capital Management first reported a position in NVCR in Q4 2018 and held it in 9 quarters. The position peaked at $15.2M in Q4 2020. 328 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Tekla Capital Management reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Tekla Capital Management sold 87,918 NovoCure shares in Q1 2021, an estimated $15.2M.
  • Tekla Capital Management first reported a position in NovoCure in Q4 2018 and held it in 9 quarters.
  • Tekla Capital Management's NovoCure position peaked at $15.2M in Q4 2020.
  • 328 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.